Blood test could revolutionize sarcoma monitoring

NCT ID NCT06068075

Ongoing Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a liquid biopsy (a blood test that detects tumor DNA) can help predict outcomes for people with Ewing sarcoma or osteosarcoma. Researchers will collect blood samples from 340 patients at diagnosis and track their health over time. The goal is to see if the amount of tumor DNA in the blood can tell doctors how aggressive the cancer is and how well treatment is working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liquid biopsy (FoundationOne Liquid CDx test)
What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict how aggressive a sarcoma is and whether treatment is working, without needing repeated tissue biopsies.
What could go wrong: This is an observational study, not a treatment trial. The test may not prove accurate enough to change patient care, and results may not apply to all sarcoma types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma Ewing sarcoma of bone extraskeletal Ewing sarcoma Neuroectodermal Tumors, Primitive, Peripheral osteosarcoma peripheral primitive neuroectodermal tumor peripheral primitive neuroectodermal tumor of bone peripheral primitive neuroectodermal tumor of soft tissues

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA EWING SARCOMA OF BONE EWING SARCOMA OF SOFT TISSUE HIGH GRADE OSTEOSARCOMA PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR OF BONE PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR OF SOFT TISSUE

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Children's Healthcare of Atlanta

Atlanta, Georgia, 30322, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Children's Hospital's and Clinics of Minnesota

Minneapolis, Minnesota, 55404, United States
Childrens Hospital Los Angeles

Los Angeles, California, 90027-0700, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Lifespan / Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Nationwide Children's Hospital

Columbus, Ohio, 43205, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Utah Childrens Medical Center

Salt Lake City, Utah, 84113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.